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Streptococcus pneumoniae (‘pneumococcus’) causes an estimated 14.5 million cases of
serious disease and 826,000 deaths annually in children <5 years of age 1. The highly
effective US introduction of the PCV7 pneumococcal vaccine in 2000 2,3 provided an
unprecedented opportunity to investigate the response of an important pathogen to a
widespread, vaccine-induced, selective pressure. Here we use array-based sequencing of 62
isolates from a US national monitoring program to study five independent instances of
vaccine escape recombination 4, demonstrating directly the simultaneous transfer of multiple
and often large (up to at least 44kbp) DNA fragments. We show that one such novel strain
quickly became established, spreading from East to West across the US. These observations
clarify the roles of recombination and selection in the population genomics of
pneumococcus, and provide proof-of-principle of the considerable value of combining
genomic and epidemiological information in the surveillance and enhanced understanding of
infectious diseases.
Childhood vaccination has proved effective against many viral and bacterial diseases, but
more sophisticated vaccine approaches will be needed for pathogens with more complex
genomes, life-cycles, and population structures, where the evolutionary responses of
organisms are likely to be a key factor. Among the earliest successful bacterial vaccines
were some for diseases (diphtheria, tetanus) where the actual cause of disease (e.g. a toxin)
is targeted directly. Conjugate vaccines, in which a bacterial polysaccharide is joined to an
immunogenic protein, have been developed for two other important childhood pathogens,
Haemophilus influenzae type B and Neisseria meningitidis type C 5-7. The success of these
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vaccine strategies was at least in part due to the relatively simple structure of the pathogen
population, and the limited variability and evolvability of the pathogen molecule(s) targeted
by the vaccine, but other organisms provide greater challenges.
Pneumococcal cells are covered by a layer of polysaccharide called the capsule, which
serves as a major virulence factor and provides a target for vaccination. The first
pneumococcal conjugate vaccine in routine use in infants was PCV7 (Pfizer), a conjugate
incorporating the polysaccharides of seven of the >92 capsular types (serotypes) introduced
to the US in 2000 to immediate and dramatic effect. By 2001, rates of invasive
pneumococcal disease in the vaccinated age group, 0-2 years, had decreased by 69% 2 and
by 2007 the rate in children <5 years old had stabilized at 24% of the level present before
the vaccine 3.
At the time of its introduction, there was considerable speculation about the likely results of
the extreme selection induced by the vaccine, and its possible downstream consequences on
vaccine efficacy and longevity 8,9. Colonization of the nasopharynx, especially of young
children, provides the major reservoir for transmission of the pneumococcus. Vaccination
reduces the rate of colonization of PCV7 serotypes, interrupting transmission while also
allowing the rate of colonization by non-vaccine serotypes to increase 10. Two mechanisms
were anticipated for this serotype replacement: demographic expansion of non-vaccine
serotype lineages and capsular switching – the replacement of the capsular gene cluster in
one genome by the non-vaccine capsular genes from a different lineage.
We combined epidemiological and genomics approaches to better understand the nature,
mechanisms, and consequences of vaccine escape. We sequenced a pre-selected subset of
12% (300kb) of the pneumococcus genome (Supplementary Figure 1) using Affymetrix
CustomSeq technology and describe data in 62 isolates ascertained for potential
epidemiological interest (Table 1). Whole-genome resequencing of several of the isolates on
the Illumina GAIIx platform was used to confirm findings of particular interest.
During 2000-2007, approximately 27000 sterile-site pneumococcal isolates had been
recovered from patients in 10 US states and serotyped by the Centers for Disease Control
and Prevention in Atlanta, USA, as part of the “ABCs” monitoring programme 3. The so-
called sequence type of 1,902 serotype 19A isolates between 2001 and 2007, collected from
patients of all ages, was then determined 4,11,12 by MLST (multi-locus sequence typing), a
widely used molecular fingerprinting approach in which (Sanger) sequence data is collected
from seven fixed ~400-500bp fragments of essential genes 13. Samples with a sequence type
not commonly associated with serotype 19A were potential examples of vaccine escape
through capsular switching 14 (Table 1; details Supplementary Table 1). We had previously
reported three distinct progeny strains, which we refer to as P1, P2, and P3, resulting from
capsular switching with serotype 4 recipients 4, which we confirmed by Sanger sequencing
to identify recombinational breakpoints. Two further instances (P4, P5) were identified in
the current study by resequencing of candidates (Supplementary Table 2). We have therefore
defined a total of 5 independent instances of vaccine escape through capsular switches
whereby serotype 4, which is included in the PCV7 vaccine, was replaced by serotype 19A,
which is not.
In addition to identifying capsular switch recombinants, our resequencing approach allowed
us to search for putative donor and recipient genomes. When one sequence takes up DNA
from another through recombination, we refer to the former as the recipient sequence and
the latter as the donor sequence. For P1 and P2, our sequencing revealed well-matched
putative recipient and donor sequences with serotypes 4 and 19A. In addition, genomic
analyses identified respectively 4 and 8 additional sequence fragments that did not match
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known serotype 4 (recipient) genomes (Figure 1 (A); Supplementary Figure 2;
Supplementary Table 3) and suggested that all the imported fragments could have originated
from a single serotype 19A donor sequence in each case. Illumina sequencing of an early P1
and its prospective donor and recipient confirmed our analysis and identified 8 extra small
imported fragments across the whole genome (Figure 1 (B)). To rule out the possibility that
the additional fragments could have come from other serotype 4 sequences that we had not
analysed, we used SNP typing to screen 88 archived US serotype 4 isolates collected around
the time PCV7 was introduced for P1- and P2-specific additional sequence fragments, and
found no alternative candidate recipients that could explain the structure of P1 and P2
without invoking multiple imports from a serotype 19A-like donor (Supplementary Note;
Supplementary Table 7; Supplementary Table 8).
Our data thus demonstrate the independent origin of each recombinant lineage and strongly
support the idea that multiple fragments may be transferred during a single episode of
recombination. Across P1-P5, conservative estimates suggest a range of 1-27 fragments
have been transferred in addition to the capsular locus, with sizes from 0.04 to at least 44 kb
(Supplementary Table 3). While it was impossible to exclude separate sequential events in
explaining each progeny structure, the observation that whenever we ascertained a capsular
recombination event we saw other serotype 19A-like imports elsewhere in the genome is
strong evidence that multiple fragments may be imported from the donor simultaneously, or
in a short time sequence. Recombination involving transfer of large fragments or multiple
fragments simultaneously has long been observed or inferred in vitro in pneumococcus 15-18.
A recent report 19 documented multiple putative transfers in a single individual. Our
findings show that such recombination events can happen not only in vitro or in individuals,
but also at population scales, becoming evident after a nationwide immunization
programme. A further recent report 20 detected several instances of capsular recombination
in the 40-year global spread of a multi-drug-resistant lineage of pneumococcus but did not
describe evidence for multi-fragment recombination, perhaps because of differences in
sampling strategy or analytical methodology.
Predictions made at the introduction of the pneumococcal conjugate vaccine in the US about
the potential for serotype replacement were confirmed by early data from the ABCs
network 2. Among all non-vaccine serotypes, 19A has increased in frequency most, for a
variety of possible reasons 12. Between 1998 and 2007, rates of invasive pneumococcal
disease caused by serotype 19A increased ~2.5-fold and its share of disease at all ages
increased from approximately 3% to 20%, reaching 47% in children under 5 3 (Figure 2;
Supplementary Table 4). Capsular switching as a means of vaccine escape was also
predicted in advance, but the success of the vaccine escape lineage P1 is still remarkable.
Isolates were first detected in New York (n = 3) and Connecticut (n = 1) in 2003 14 and have
spread westward in subsequent years. Since 2003, P1 has become one of the most prevalent
genotypes in post-vaccine populations, having been recovered from 175 patients of all ages
by the end of 2007. In contrast, three of the other four vaccine escape lineages we detected,
P3-P5, have been seen only once in our screen, and P2 has been observed 8 times,
predominantly in the northeastern US.
The spread of vaccine escape recombinant P1 and to a lesser extent P2 has also allowed us
an unprecedented opportunity to observe pneumococcal evolution in real populations in real
time. Genomic analyses of the evolution of the P1 and P2 lineages demonstrate that
recombination events have continued to occur and imply that when recombination can be
definitively inferred it tends to involve multiple genomic fragments (Supplementary Note;
Supplementary Figure 3). With no ascertainment bias to favour recombination episodes
involving a large transferred sequence such as the capsular locus, these data are consistent
with a model of variable numbers of smaller transferred sequences and with published
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estimates of the relative rates of recombination and mutation 20,21. Depending on the
assumptions made, the proportion of new variation within the P1 and P2 recombinant
lineages that has arisen due to recombination can be estimated at at least ~60% (details in
Supplementary Note).
In this study we have observed, in 5 separate vaccine escape lineages and during the
subsequent evolution of two of those lineages, 11 separate episodes of recombination
leading to the import of sequences into a pneumococcal genome. In only two of these
episodes was there no evidence for transfer of multiple separate fragments and so we
conclude that multi-fragment recombination is commonplace in pneumococcal populations.
One consequence of this is that even the terminology “capsular switch” is potentially
misleading because it suggests that only the capsular locus has been transferred.
Documentation of multi-fragment recombination in real populations is particularly
interesting because it has profound consequences for the way in which an organism may be
able to traverse its evolutionary fitness landscape. For example, moderate to high level beta-
lactam class antimicrobial resistance is usually associated with horizontal transfer of variants
at three dispersed pbp loci, and drug resistance took about two decades after the introduction
of penicillin to first emerge in pneumococcus. Having emerged, penicillin resistance
determinants now spread rapidly from one genetic background to another under drug-
induced selective pressure and pose a significant threat to treatment. Multi-fragment
recombination could also have been important in generating the (currently unknown)
factor(s) which allowed P1 to surpass many other non-vaccine lineages in invasive disease
incidence. The recent introduction of a 13-valent pneumococcal conjugate vaccine including
serotype 19A in the US and elsewhere is likely to reduce significantly the impact of serotype
19A on vaccinated populations, but how many, and which, serotypes will be needed for a
vaccine that provides acceptable long-term disease reduction are still unknown.
Modern high-throughput molecular technologies now allow typing of bacterial isolates on a
genomic scale, thus providing much greater resolution than current, standard, MLST
approaches. We have described a proof-of-principle experiment which confirms the
potential for combining genome-scale genetic information with epidemiological data, in this
case in better understanding serotype replacement following introduction of a conjugate
vaccine. We identified five independent instances of vaccine escape through capsular
switching from serotype 4 to 19A. Our genomic data provide strong evidence that in each
case the recombination event generating the capsular switch involved simultaneous import
of multiple and often large additional DNA fragments around the genome. This process has
far-reaching consequences for the evolution of bacteria and their response to the strong
selection imposed by vaccines or antimicrobials. It may also play a role in the striking
success of the P1 vaccine escape lineage as an invasive pathogen among the 19A lineages
present after vaccine introduction. While vaccine escape through capsular switching was
correctly predicted in advance of the vaccination programme, our analyses show that,
particularly in the light of complex recombination mechanisms, its specific consequences
are difficult to predict.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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APPENDIX
Online Methods
More detailed methods and preliminary results are included in Supporting Materials.
Polymerase chain reaction (PCR) and Sanger sequencing for MLST and other sequence
typing used standard methods 4,13. Primer sequences targeting the upstream and downstream
recombination breakpoints are shown in Supplementary Table 5. The GeneChip CustomSeq
platform (Affymetrix, Santa Clara, CA, USA) 23,24 was used to target a 300kb subset of the
S. pneumoniae genome for resequencing. Sequence fragments were selected and optimized
for inclusion in a custom array design (Supplementary Figure 1). Samples were processed
according to the maker’s instructions: 16μg of genomic DNA was labelled and hybridized to
an array, the array was washed and scanned and hybridization data was analysed using
onboard software. Sequence calls were filtered using a bespoke method designed to produce
high-accuracy calls from diverse sequences (Supplementary Table 6; details in
Supplementary Note). PCR-RFLP (PCR-restriction fragment length polymorphism) analysis
for SNP typing used fluorescently labelled primers (Supplementary Table 7) according to
established protocols and data was collected on an ABI3730 automated sequencer. Illumina
sequencing on the Genome Analyzer IIx platform (Illumina, San Diego, CA, USA)
employed standard methods to produce 51b paired reads which were assembled using
Velvet 25 and then aligned to a reference sequence using Mauve 26. Bioinformatic analyses
used Python and R 27.
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Resequencing of pneumococcal vaccine escape recombinants: comparison of recombinant
and putative recipient and donor sequences.
(A) Vaccine escape recombinants P1-P5 were resequenced using the Affymetrix CustomSeq
platform, a microarray-based approach covering a selected 12% of the pneumococcus
genome (300 kbp). The genomes are coloured by inferred origin of genomic intervals (blue -
recipient; yellow - donor). The capsular locus transferred in a different form in each
recombinant is evident as a large yellow block centred on the same location towards the left
of each genome. Other yellow blocks indicate extra transferred sequences. The recipient
genomes in all cases were highly similar.
(B) Whole-genome structure of recombinant P1. Representatives of recombinant P1 and its
best-matching prospective parents were sequenced on the Illumina GAIIx platform.
Sequence reads were assembled de novo and aligned to the TIGR4 reference sequence 22
and a heuristic algorithm was implemented in which three or more donor-like single
nucleotide variants encompassing no more than one recipient-like variant was used to
identify donor genomic fragments (blue - recipient; yellow - donor). This approach detected
15 imports of ≥50bp, including 8 that did not overlap previously detected fragments. The
scale in (B) is different to that in (A) because the reference sequences differ slightly. In each
panel the smallest fragments (triangles) have been magnified to a minimum size of 5kb for
visibility.
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Spread of P1 vaccine escape recombinant through space and time.
Incidence of P1 vaccine escape recombinants (red) and other 19A (blue) as a proportion of
all pneumococci in invasive pneumococcal disease among children under 5 years of age.
Data are shown for the years 2003-2007; left to right panels for each state in 10 ABCs
monitoring states. Data from 2003 in New Mexico are missing (grey box) because
surveillance started there in 2004. P1 was first detected in New York and Connecticut from
where it has spread westwards.
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